Fulgent Genetics, Inc. - 8-K Filing
Fulgent Genetics announced that its full abstract presenting interim data from a Phase 2 study of FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) was released. The trial showed an objective response rate (ORR) of 60% across two arms, median progression-free survival (mPFS) of 7.2 months, and a favorable safety profile with mostly grade 1-2 adverse events. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $FLGT